A couple of Trickle holdings get new coverage today:
>>Initiates Ratings On Arena Pharmaceuticals, Bruker Daltonics, Millennium Pharmaceuticals and Waters Corp.
MINNEAPOLIS, May 2, 2001 (BUSINESS WIRE) -- Dain Rauscher Wessels equity analyst Todd Nelson today introduced coverage of the following four biotechnology companies:
-- Waters Corp. (NYSE: WAT chart, msgs), $55.68, with a Strong Buy-Average
Risk rating and 12-month price target of $73.
-- Arena Pharmaceuticals Inc. (Nasdaq: ARNA chart, msgs), $20.64, with a
Buy-Aggressive Risk rating and 12-month price target of $29.
-- Bruker Daltonics Inc. (Nasdaq: BDAL chart, msgs), $13.65, with a
Buy-Aggressive Risk rating and 12-month price target of $20.
-- Millennium Pharmaceuticals Inc. (Nasdaq: MLNM chart, msgs), $36.46, with a
Buy-Aggressive Risk rating and 12-month price target of $54.<<
snip
Trickle manager will be climbing in Red Rocks near Vegas starting Saturday and will miss most of next week (back by Friday). Counting on fellow TrickleMavens to cover QGENF, BDAL, EBIO, & PBSC. (5/8 - 5/10)
PCOP reports after the close today, and CRL and AGNT report tomorrow. A busy earnings season for Trickle!
Cheers, Tuck |
